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From October 1989 to February 1992, 74 patients with mediastinoscopicaUy staged 
IIIA (N2) non-small-cell lung cancer from 30 CALGB-atfiliated hospitals received 
two cycles of preresectional cisplatin ndvinblastine chemotherapy. Patients with 
responsive or stable disease underwent s andardized surgical resection a d radical 
lymphadenectomy. Patients who underwent resection received sequential djuvant 
therapy with two cycles of cisplatin and vinblastine, followed by thoracic irradiation 
(54 Gy after complete resection a d 59.4 Gy after incomplete resection or no 
resection at 1.8 Gy per fraction). There were no radiographic complete responses to 
the neoadjuvant chemotherapy, although 65 (88%) patients had either a response or 
no disease progression. During induction chemotherapy, disease progressed in seven 
patients (9%). Sixty-three patients (86%) had exploratory thoracotomy, and 46 of 
those (75%) had resectable lesions. A complete surgical resection was accomplished 
in 23 patients, and 23 patients had an incomplete resection with either a diseased 
margin or diseased highest node resected. Operative mortality was 3.2% (2/63). In 10 
patients (22% of the 46 having resection) the disease was pathologically downstaged. 
There was no correlation between radiographic response to the induction chemo- 
therapy and downstaging at surgical resection. The fuli protocol was completed by 
33 patients (45% of original cohort). Overall survival at 3 years was 23%. 
Patients undergoing resection had significantly improved survival at 3 years 
compared with patients not having resection: 46% for complete resection 
(median 20.9 months), 25% for incomplete r section (median 17.8 months), and 
0% for no resection (median 8.5 months). Five deaths occurred during the 
treatment period. A total of 18 of the 46 (39%) patients who underwent resection 
are either alive and disease-free or have died without recnrrence. (J THORAC 
CARDIOVASC SURG 1995;109:473-85) 
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S urgical resection alone in stage IIIA (N2) non- small-cell ung cancer is associated with poor 
survival. Five-year survival ranges between 5% for 
clinically diagnosed N2 disease to 29% for occult N2 
disease found on pathologic staging. 1-3 Less than 
10% of patients found to have occult N2 disease by 
preresectional staging mediastinoscopy who are 
then treated with surgery and postoperative radia- 
tion therapy achieve 5-year survival. 4 Similarly, ra- 
diation therapy alone consistently produces median 
survivals of less than 1 year and 5-year survivals 
between 5% and 10%. 5-7 
Preoperative 4'8'9 and postoperative radiation 
therapy 1°has been used in an attempt to improve 
survival in these patients. Although preoperative 
radiation therapy improves resectability rates and 
both strategies improve local control, neither strat- 
egy improves survival. The pattern of treatment 
failure is altered with radiation therapy. Local fail- 
ure is reduced but relapse in distant sites increases, 
suggesting micrometastatic disease at the time of 
resection. 
Multimodality combinations uch as preresec- 
tional chemotherapy followed by surgery and adju- 
vant chemoradiation therapy offer several theoreti- 
cal advantages. 11 The preresectional delivery of the 
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chemotherapeutic agents is not adversely affected by 
alterations in regional blood flow that accompany 
surgical scar or radiation therapy. The chemother- 
apy, if effective, may lead to increased resectability 
rates, downstaging of the original extent of disease, 
and a decrease in the risk of tumor dissemination 
during surgical resection. The chemotherapy may 
serve as a radiosensitizing agent with enhancement 
of local control and may lead to increased control of 
systemic disease by treating micrometastases. 
These potential advantages are counterbalanced 
by theoretical disadvantages. Preoperative chemo- 
therapy is accompanied by a delay before resection 
with possible disease progression during that inter- 
val. The induction therapy can be expected to carry 
its own morbidity and possible mortality, and the 
combination of treatment modalities within a short 
time frame may augment he individual treatment 
toxicities. The prolonged treatment regimen may 
also adversely affect he period of remission that the 
patient can expect before disease progression and 
may lead to a drop in functional status. Finally, if the 
induction chemotherapy is not well tolerated, surgi- 
tal resection may not be feasible, so that the single 
best mode of therapy is precluded. 
Several trials of combined multimodality proto- 
cols in the treatment of patients with stage IIIA 
non-small-cell lung cancer have been reported. 12-a7 
Despite this, the best treatment for patients with N2 
disease remains unclear for several reasons. First, in 
a number of trials, 12q4' 17 eligible patients have 
included those whose disease was staged IIIA by 
noninvasive imaging of the mediastinum, although 
there is evidence that a considerable number of 
patients will have false-positive and false-negative 
results from noninvasive staging, is Second, some 
trials13, 14, 17,19 have combined patients considered 
to have stage IIIA disease by virtue of chest wall or 
mediastinal pleural invasion (T3 NO or T3 N1) with 
those who have diseased ipsilateral mediastinal 
nodes (N2). This former group of patients may have 
a slightly bettet prognosis than patients with ipsilat- 
eral mediastinal node disease, so that it is diIficult to 
judge the efficacy of new treatments on each of the 
two separate subsets of IIIA non-small-cell ung 
cancer.2, 3,20 
The purpose of this prospective phase II multiin- 
stitutional trial of the Cancer and Leukemia Group 
B (CALGB protocol 8935) was to assess the feasi- 
bility, efficacy, and toxieity of neoadjuvant chemo- 
therapy and postoperative, sequential chemother- 
apy and thoracic radiotherapy in the treatment of 
patients with pathologically confirmed stage IIIA 
(N2) non-small-cell lung cancer. Specifically, the 
trial sought to quantify the percentage of patients 
undergoing thoracotomy and resection, the patho- 
logic response to the induction chemotherapy, the 
toxicity associated with combined treatments, the 
surgical morbidity and mortality, the long-term sur- 
vival, and the pattems of recurrence for patients 
treated in this trimodality manner. 
Patients and methods 
Patient eligibility. Only patients with histologically 
documented stage IIIA non-small-cell ung cancer with 
metastases to the ipsilateral mediastinal nodes (Tl-3, N2) 
were eligible. Patients with T3, N0-1 lesions were ineligi- 
ble. 
All patients underwent a staging cervical mediastinos- 
copy with evaluation of bilateral node stations 2and 4 and 
subcarinal station 7 as defined by the American Thoracic 
Society. 21 For patients with primary lesions of the left 
upper lobe, an initial anterior mediastinotomy with biopsy 
of station 5 or 6 nodes was generally done. If station 5 or 
6 was involved, the anterior mediastinotomy was always 
followed by cervical mediastinoscopy and contralateral 
lymph node biopsy before study entry. Patients with 
extracapsular nd intracapsular lymph node involvement 
were eligible. The results of the staging procedures were 
documented and patients were evaluated by a thoracic 
surgeon, medical oncologist, and radiation oncologist 
before the initiation of the treatment protocol. The pri- 
mary tumor size was determined and followed by a chest 
computed tomographic (CT) scan or radiograph to assess 
response to chemotherapy. 
In addition to histologic evidence of disease, eligibility 
criteria also included the following: at least 18 years of 
age, informed consent, expected survival 2 years or more, 
Eastern Cooperative Oncology Group performance status 
of 0 to 1, predicted postoperative forced expiratory vol- 
ume in 1 second (FEV1) greater than 900 tal, and 
candidate for postoperative thoracic irradiation. Except 
for postobstructive pneumonia, ll active infections had to 
be controlled. Presence of serious psychiatric or medical 
illness that was perceived to preclude informed consent or 
survival for 2 years or less was grounds for ineligibility. 
The required laboratory values were as follows: granulo- 
cytes more than 1800/txl; platelets more than 100,000/~1; 
hemoglobin value more than 10 gin/dl; total bilirubin level 
less than 1.5 mg/dl; blood urea nitrogen level less than 1.5 
times normal; creatinine content less than 1.5 mg/dl or 
creatinine clearance 60 tal/min or more; room air oxygen 
tension more than 50 torf; and carbon dioxide tension less 
than 50 torr. 
Treatment. The treatment plan is graphically summa- 
rized in the schema of Fig. 1. Planned treatment began 
with vinblastine 5 mg/m 2 intravenous (IV) bolus given 
weekly for 5 weeks (days 1, 8, 15, 22, and 29) and two 
doses of cisplatin 100 mg/m 2IV given 4 weeks apart (days 
1 and 29) before surgical resection. 
After induction chemotherapy, the disease was clini- 
cally restaged in all patients. Patients with progressive 
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Fig. 1. Schema summarizing the treatment plan in CALGB protocol 8935. Induction chemotherapy was 
two cycles of vinblastine (V) 5 mg/m 2per week and cisplatin (P) 100 mg/m 2given on days 1 and 29. Surgical 
resection was generally on day 57. Adjuvant chemotherapy was two additional cycles of vinblastine 5 mg/m 2
per week and cisplatin 100 mg/m 2given on days 92 and 120. Adjuvant radiotherapy (XRT) was then given 
from day 155 to approximately day 200. 
disease during neoadjuvant chemotherapy were removed 
from the study and followed up for survival. Progressive 
disease was defined as an increase of more than 25% in the 
primary lesion over the size present at study entry or a 
definite increase in tumor size along with the appearance 
of new lesions. Stable disease was defined as a change in 
the size of the measured lesions between a50% reduction 
and a 25% increase with no additional disease discovered. 
Partial response was defined as a reduction of greater than 
50% in the sum of the products of the cross-sectional 
diameters of all measurable l sions and the absence of 
new lesions. Complete response was defined as the disap- 
pearance of all measurable intrathoracic disease. Patients 
with response or stable disease underwent thoracotomy 
and attempted standard curative resection approximately 
4 weeks after the last dose of chemotherapy. 
The surgical procedure was based on the extent of 
tumor at the time of initial presentation rather than at the 
time of thoracotomy and consisted of a lobectomy, sleeve 
resection, bilobectomy, or pneumonectomy. The choice of 
operative procedure was made by the attending surgeon 
and was based on curative intent while preserving as much 
functional lung volume as possible. 
A complete ipsilateral superior mediastinal lymphade- 
nectomy was performed in all cases (resection of ipsilat- 
eral nodal stations 2, 4, 7, and 10). For patients with 
primary lower lobe lesions, station 9 lymph nodes were 
also resected. Patients with primary left upper lobe lesions 
also had resection of stations 5 and 6 lymph nodes. All 
ipsilateral hilar nodes were removed en bloc with the 
primary surgical specimen. Additionally, any grossly ab- 
normal nodes found at operation outside these stations 
were removed and examined. All resected nodal groups 
were individually labeled by the surgeon at the time of the 
operation. 
Patients were considered to have undergone resection 
so long as the primary tumor was excised and mediastinal 
node dissection was completed. Disease-free margins 
were considered to indicate complete resection. Diseased 
margins, diseased highest node sampled, and minimal 
gross disease left behind were considered to indicate 
incomplete resection. Known areas of residual tumor were 
clipped for later use in determining radiotherapy portals. 
The surgeon was obligated to obtain biopsy tissue of 
residual disease in patients who could not undergo resec- 
tion. If thoracotomy revealed unresectable disease, the 
patient remained in the protocol but received no further 
chemotherapy and proceeded irectly to postoperative 
thoracic irradiation to 59.4 Gy. 
Patients who underwent resection began postoperative 
chemotherapy 4 to 6 weeks after thoracotomy. Adjuvant 
chemotherapy consisted of vinblastine 5 mg/m 2 IV bolus 
biweekly for a total of four doses beginning on day 92 of 
treatment (days 92, 106, 120, and 134) and two doses of 
cisplatin 100 mg/m 2IV 4 weeks apart (days 92 and 120). 
After adjuvant chemotherapy, patients underwent re- 
peat pulmonary function tests before the start of adjuvant 
radiation therapy. Patients with an FEV1 of 900 ml or 
more after chemotherapy and surgery began radiotherapy 
within 35 days of the last chemotherapy treatment (90 
days from thoracotomy). Patients with an FEV1 less than 
900 ml did not receive adjuvant radiotherapy but were 
followed up for survival. 
Patients having complete resection received a conven- 
tionally fractionated total thoracic dose of 54.0 Gy of 
adjuvant radiation therapy by means of a shrinking field 
technique. The initial volume treated the bronchial stump, 
ipsilateral hilum, bilateral supraclavicular fossae, upper 
mediastinum, subcarinal space, and any initially involved 
nodal stations within the lower mediastinum to 36.0 to 
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Table I. Patient demographics and clinical staging 
in CALGB protocol 8935 (n = 74 patients with 
stage lilA (N2) non-small-cell lung carcinoma) 
No. Percent 
Sex 
Male 50 68 
Female 24 33 
Race 
White 69 93 
Black 5 7 
Age (yr) 
Median 52 
Range 45-75 
40-49 15 20 
50-59 26 35 
60-69 27 37 
70+ 6 8 
Weight loss 
<5% 63 85 
>5% 7 10 
Unknown 4 6 
Symptoms 
<3 mo 42 57 
3-6 mo 18 24 
>3 mo 7 10 
Unknown 7 10 
Histology 
Adenocarcinoma 26 35 
Squamous cell 32 43 
Large-cell 7 10 
Undifferentiated 9 12 
' Primary 
T1 7 10 
T2 50 67 
T3 17 23 
39.6 Gy at 1.8 Gy per fraction once a day. The "boost 
volume" treated the bronchial stump, ipsilateral hilum, 
and initially involved mediastinal nodal stations to a total 
cumulative dose of 54.0 Gy also at 1.8 Gy per fraction. 
Patients with incompletely resected or unresectable 
disease received a total thoracic dose of 59.4 Gy at 1.8 Gy 
per fraction once a day. The initial volume for these 
patients was the same as for those patients with com- 
pletely resected isease but also included any residual or 
gross disease at the primary site. This initial volume was 
also treated to 36.0 to 39.0 Gy. The boost volume was also 
the same as for those patients with completely resected 
disease but now included any initial sites of gross or 
residual tumor and involved mediastinal nodal stations. 
However, this boost volume was treated to a total cumu- 
lative dose of 59.4 Gy. 
Patients who were ineligible for continuation i  the 
study because of progressive disease or other conditions 
were eligible for palliative radiotherapy at the discretion 
of the radiotherapist. No prophylactic cranial irradiation 
was used. All radiotherapy treatments were centrally 
reviewed by the Quality Assurance Review Center. 
Follow-up. Patients are being evaluated in an outpa- 
tient clinic every 2 months for 2 years, then every 4 months 
for 2 years, and yearly thereafter. Clinic visits included a
history, physical examination, and posteroanterior and 
lateral chest x-ray films. Head CT, chest CT, and bone 
scans were required when clinical signs of recurrence 
developed. Histologic confirmation of recurrence was 
strongly encouraged. 
Statistics. The Kaplan-Meier product-limit estimator 22
was used to estimate the survival curve and failure-free 
survival curves. The log-tank test was used to compare the 
survival experience of subgroups. 
Results 
Patients characteristics. From October 1989 to 
February 1992, 80 patients from 30 CALGB-affili- 
ated hospitals were enrolled in the study. Six pa- 
tients were ultimately declared ineligible, leaving 74 
patients for analysis. The six ineligible patients 
included four patients found to have stage IIIB 
disease (two had T4 primary tumors, one had a 
malignant pleural effusion, and orte had contralat- 
eral mediastinal node disease), one patient found to 
have distant metastases at the time of registration, 
and one patient who withdrew consent and was not 
treated. 
The demographic variables and tumor classifica- 
tion of the 74 evaluable patients are summarized in 
Table I. Fifty patients were male (68%) and 24 
female (33%). Sixty-nine patients were white (83%) 
and five were black (7%). Ages ranged from 45 to 75 
years with a median of 52 years. All patients tudied 
were Eastern Cooperative Oncology Group perfor- 
mance status 0-1. Weight loss in the previous 6 
months before study entry was less than 5% in 63 
(85%) and greater than 5% in seven (10%) patients. 
Symptoms had been present for less than 3 months 
in 42 patients (57%), greater than 3 months in 25 
(34%), and present for an unknown period in seven 
(10%). Histologic cell type of the final pathology 
specimen showed 26 patients had adenocarcinoma 
(35%), 32 had squamous (43%), seven had large-cell 
(10%), and nine had undifferentiated (12%) non- 
small-cell lung cancer. The primary tumor at initial 
presentation was classified clinically as T1 in seven 
(10%), T2 in 50 (67%), and T3 in 17 (23%). All 
patients had N2 nodal disease. 
All 74 patients had surgical staging of the medi- 
astinal lymph nodes with cervical mediastinoscopy 
or anterior mediastinotomy. All patients had histo- 
logically proved N2 disease of the ipsilateral medi- 
astinum. 
Response to induction chemotherapy. None of 
the patients had radiographic complete responses to 
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Fig. 2. Progression of patients through protocol treatment. Of the 74 patients offered preresectional 
chemotherapy, 63 patients progressed to exploratory thoracotomy. At operation, 17 patients had 
unresectable sions and were followed-up for survival, with 11 of these patients receiving adjuvant 
radiotherapy (RT). Of the 23 patients with an incomplete resection, 20 received adjuvant chemotherapy 
and 15 of these completed the entire adjuvant protocol. Of the 23 patients with a complete resection, 20 
received adjuvant chemotherapy and 16 of these completed the entire adjuvant protocol. 
induction chemotherapy. Sixty-five (88%) had a 
partial response or stable disease, six (8%) had 
progression of disease, and three (4%) had an 
unevaluable radiographic response. 
Fig. 2 summarizes the flow of the patient cohort 
through the treatment protocol. Sixty-three (86%) 
of the 74 patients proceeded to exploratory thora- 
cotomy whereas 11 patients did not continue the 
protocol beyond the induction chemotherapy. Six of 
the 11 patients had clinical progression of their 
tumor at restaging: one of six patients received a 
single cycle of chemotherapy and was then found to 
have an increase in the size of the primary and 
satellite pulmonary lesions, three of six patients 
received two cycles of anterior chemotherapy and 
had a greater than 25% increase in the size of the 
primary lesion, and two of six patients had two cycles 
of chemotherapy and were then found to have 
distant metastases (one liver and one bone). One of 
the 11 patients received two cycles of anterior 
chemotherapy with a partial radiographic response 
in the tumor but then refused to have the operation. 
Another of the 11 patients was lost to follow-up for 
a 2-month period after having a partial response to 
the two cycles of chemotherapy. When she returned, 
the primary tumor had progressed to stage IIIB and 
she was treated oft protocol with radiation therapy. 
The participation of two of the 11 patients was 
terminated because of treatment toxicities. The first 
patient was a 78-year-old man who had moderately 
severe bon° marrow suppression, esophagitis, co- 
lonic ulcers, and peripheral edema after a single 
cycle of chemotherapy with deterioration in his 
medical condition necessitating a prolonged stay in 
the intensive care unit. The second patient was a 
77-year-old man with reversible severe nephrotoxic- 
ity after a single cycle of chemotherapy. 
Grade 3 (severe) and grade 4 (life-threatening) 
toxicities of the induction chemotherapy are sum- 
marized in Table II. No grade 5 (lethal) toxicities 
occurred. The most common toxicity was myelosup- 
pression, with severe granulocytopenia developing in 
67% of the 74 patients. On° patient died during the 
induction chemotherapy from a pulmonary embolus. 
This was not considered a treatment-related death. 
Surgical results. Forty-six patients (75% of the 
63 undergoing exploration) had resectable disease. 
Twenty-three patients (36.5%) had a complete sur- 
gical resection, 23 patients (36.5%) had an incom- 
plete resection (seven had a diseased margin, 11 had 
a diseased highest node resected, and four had both 
a diseased margin and highest node), and 17 pa- 
tients (27%) had unresectable sions. Twenty-five 
patients were treated with a curative lobectomy, 17 
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Table II. Major toxicities of induction 
chemotherapy (n = 74) 
Grade 3 Grade 4 
No. % No. % 
White blood cells 22 28 9 11 
Granulocytes 14 18 38 49 
Lymphocytes 13 22 1 1 
Infection 5 6 0 
Nausea 4 5 0 
Diarrhea 2 3 1 1 
Azotemia 4 5 0 
Renal failure 0 1 1 
Stomatitis 0 1 1 
Dyspnea 0 1 1 
Edema 1 1 1 1 
Total 65 53 
with pneumonectomy, two with a sleeve lobectomy, 
and two with a lobectomy and chest wall resection. 
In 10 patients (22% of the 46 patients having 
resection) the tumor was pathologically downstaged 
at resection: four patients (9%) had only N1 dis- 
eased nodes (stage II) and six (13%) patients had no 
tumor identified in N1 or N2 nodes (stage I). Ten 
patients (22%) had a diseased level 2 node and 10 
patients (22%) had a diseased level 7 node in the 
pathologic specimen. No pathologic omplete re- 
sponses were obtained. 
There was no correlation between radiographic 
response to the neoadjuvant chemotherapy and 
downstaging at surgical resection. All patients 
whose tumor class was downstaged to stage II 
disease had been listed as having stable disease. Of 
the six patients whose tumor class was downstaged 
to stage I, three had stable disease, two a partial 
response to the chemotherapy, and one had an 
unevaluable response. Of seven patients found to 
have only microscopic foci of viable tumor within 
the primary lesion, four had been classified with a 
stable response (all with a T2 original lesion) and 
three a partial response to the chemotherapy (one 
originally with a T3 lesion and two with T2 primary 
tumors). 
The operative mortality was 3.2% (two patients). 
One patient had postoperative r spiratory failure 
and died on postoperative day 151, and the other 
patient died on postoperative day 51 of postopera- 
tive pneumonia. Both deaths are considered treat- 
ment related. 
Postoperative morbidity is summarized in Table 
III. Five patients (9% of those reported) had post- 
operative pneumonia, four (6% of reported) had 
Table III. Operative morbidity (n = 63) 
No. Percent 
Supraventricular t chycardia 4 7 
Pneumonia 5 9 
Tracheostomy 2 3 
Respiratory failure 2 3 
Bronchopleural fistula and 3 5 
empyema 
Wound infection 1 2 
Atelectasis necessitating 1 2 
bronchoscopy 
supraventricular tachycardias, and two (3% of re- 
ported) had respiratory failure necessitating reintu- 
bation and mechanical ventilation. A bronchopleu- 
ral fistula and empyema developed in three patients 
(5% of reported). 
Sequential adjuvant therapy. Thirty-three pa- 
tients of the 46 undergoing resection (69%) com- 
pleted the full adjuvant protocol. 
Of the 46 patients undergoing resection, six re- 
ceived no additional protocol therapy. One of the six 
patients with an incomplete resection was identified 
as having occult brain metastases after a seizure in 
the immediate postoperative period. One patient 
with an incomplete resection and one patient with a 
complete resection died after the operation, as 
reported earlier. Another patient with a complete 
resection and an additional patient with an incom- 
plete resection refused further therapy but are in- 
cluded in the survival analysis according to the type 
of resection. Eleven of the 17 patients with unre- 
sectable lesions received postoperative radiation 
therapy oft protocol, and an additional six received 
no further therapy. 
Grade 3 (severe) and grade 4 (life-threatening) 
toxicities associated with postoperative chemother- 
apy are summarized in Table IV. No grade 5 (lethal) 
toxicities to the adjuvant chemotherapy developed. 
Myelosuppression was the most common toxicity, 
with 43% of patients having severe granulocytope- 
nia. 
Six patients discontinued protocol therapy during 
the period of postoperative chemotherapy: two had 
progressive disease, two patients withdrew consent 
for further therapy, and two patients died (one of a 
pulmonary embolus and the other of sepsis). 
Of the 44 patients eligible for thoracic radiation 
therapy, 42 (95%) completed irradiation as planned; 
this group included 16 of 17 patients with com- 
pletely resected disease, 16 of 16 patients with 
incompletely resected isease, and 10 of 11 with 
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unresectable tumor. One of the two patients failing 
to complete irradiation had an unresectable tumor 
that progressed after the patient had received only 
16.2 Gy to the thorax; the other patient had under- 
gone resection and was treated to 50.4 Gy until 
radiation therapy was discontinued because of grade 
3 toxicity (esophagitis, anorexia, and pneumonitis). 
Grade 3 (severe) and grade 4 (life-threatening) 
toxicities that developed uring adjuvant radiother- 
apy are summarized in Table IV. The hematologic 
toxicities that occurred uring the period of radia- 
tion therapy are believed to be late toxic effects of 
the postoperative chemotherapy. No grade 5 (le- 
thal) toxicities to adjuvant radiotherapy developed. 
Overall, radiation-related grade 3 or greater toxicity 
measured 2.4%, indicating consolidative radiation 
therapy was fairly well tolerated after "sandwich 
chemotherapy" and surgery. 
Survival and recurrence. Overall, five deaths oc- 
curred during treatment (6.7% of the full cohort): 
one because of pulmonary embolus during the in- 
duction chemotherapy, two because of operative 
complications, and two during adjuvant chemother- 
apy. Four of the five deaths (5.4% of the full cohort) 
were considered treatment related. 
Median follow-up of patients currently alive is 
23.6 months. Overall 1-year, 2-year, and 3-year 
survivals are 63%, 34%, and 23%, respectively. Fig. 
3 stratifies urvival after thoracotomy according to 
type of resection with corresponding numbers of 
patients at risk per year survival. Median survival for 
patients with a complete resection was 20.9 months, 
compared with 17.8 months for those with incom- 
plete resections and 8.5 months for those without 
resection (p = 0.03). The curves for the patients 
having complete resection and incomplete resection 
are better than those of patients with unresectable 
tumors throughout their course. Three-year survival 
was 46% (95% confidence interval of 19% to 73%) 
for patients having complete resection, 25% (95% 
confidence interval 10% to 47%) for those having 
incomplete resection, and 0% for those with unre- 
sectable lesions. Three-year failure-free survival was 
36% after complete resection and 21% after incom- 
plete resection. Fig. 4 shows disease-free survival of 
those patients who underwent resection and com- 
pleted the full protocol treatment, stratified by type 
of resection. Seven of the 16 (44%) patients with 
complete resection and full treatment remain dis- 
ease-free, compared with four of the 17 (24%) 
patients with an incomplete resection and full treat- 
ment (p = not significant). 
Table IV. Major toxicities of sequential djuvant 
therapy 
Grade 3 Grade 4 
No. % No. % 
Induction chemotherapy (n = 40) 
White blood cells 6 15 1 3 
Granulocytes 3 8 14 35 
Lymphocytes 6 15 1 3 
Nausea 5 13 0 
Azotemia 3 8 0 
Cardiac function 1 3 0 
Dyspnea 1 3 0 
Hearing 1 3 0 
Total 26 16 
Radiation therapy (n = 33) Grade 3 Grade 4 
White blood cells 1 3 0 
Granuloeytes 0 1 3 
Lymphocytes 5 15 8 24 
Stomatitis 1 3 0 
Pneumonitis 1 3 
Fever i 3 
Total 9 9 
Recur ence has been detected in 12 of the 23 
patients who had complete resection: local disease 
only in one, distant disease only in nine, and both 
local and distant disease in two. One patient has 
died while remaining disease-free, one patient has 
died with an unknown recurrence status, and nine 
(39%) patients remain alive and disease-free. Of the 
23 patients who had incomplete resection, 15 have 
had a recurrence: none with local disease only, seven 
patients with distant disease only, and eight patients 
with both local and distant disease. Three patients 
have died while remaining disease-free and five 
(22%) patients remain alive and disease-free. Eigh- 
teen of the 46 (39%) patients who had resection are 
either alive and disease-free or have died without 
recurrence. Of the 27 recurrences, 11 (41%) have 
included brain metastases. 
Diseussion 
CALGB protocol 8935 was designed in 1989 as a 
multiinstitutional phase II trial of high-intensity 
trimodality therapy for patients with surgically 
staged IIIA (N2) non-small-cell ung can¢er. It 
¢ombined two cy¢les of neoadjuvant cisplatin and 
vinblastine with standardized surgical resection and 
radical ymphadenectomy, then sequential djuvant 
therapy of two additional cy¢les of cisplatin and 
vinblastine followed by 54 to 60 Gy radiation ther- 
apy. Because surgical staging of the mediastinal 
nodes was required before proto¢ol entry, a homo- 
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geneous group of patients with stage IIIA (N2) 
non-small-cell lung cancer who had a poor prognosis 
was selected for analysis. 
Conducting this protocol proved to be feasible in 
a multiinstitutional setting. Enrollment for this 
phase II trial was completed in 28 months. Despite 
the participation of 30 separate teams of surgeons, 
medical oncologists, radiation oncologists, surgical 
pathologists, and data managers, protocol treatment 
and its provisions were carried out as planned in the 
74 eligible patients. Disease progression during in- 
duction chemotherapy was uncommon, occurring in 
seven of 74 patients (9%). The treatment plan was 
well tolerated with a total of four (5%) treatment- 
related deaths (two after operation and two after 
chemotherapy). The resectability rate was high. 
Eighty-six percent of all patients underwent explo- 
ration and 75% of those patients underwent resec- 
tion. The operative mortality (3.2%) and morbidity 
(30%) were comparable to previous thoracotomy- 
associated rates without he use of chemotherapy or 
radiation therapy. 23 Downstaging on the basis of the 
final pathologic specimen was possible in 22% of the 
patients subjected to resection. The addition of 
adjuvant chemotherapy and sequential radiation 
therapy may account for the lack of difference in the 
survival curves between the patients having com- 
plete and incomplete resection for the first 2 years of 
follow-up, the lack of difference in the failure-free 
survival for the first 18 months after thoracotomy, 
and the lack of difference in recurrence rates. The 
divergence in these survival curves after 2 years, 
however, suggests that complete surgical resection 
still plays a substantial role in long-term survival in 
this stage of disease. The greatest contribution of 
this treatment plan to the management of patients 
with N2 disease may be the increased resectability 
rates, with a concomitant increase in the ability to 
completely resect the tumor, because the 3-year 
survival of 46% was achieved in patients who had 
complete resection. Additionalty, the majority of 
recurrences occurred in distant sites rather than 
local or locoregional areas. 
Several other reports of induction chemotherapy 
or combined chemoradiation therapy have observed 
a high response rate, high resectability rate, and im- 
proved survival in patients with a complete resection. 
The resectability rate of 62% of all eligible patients in 
this study compares favorably with the single-institu- 
tion induction chemotherapy trial from Toronto 
(56%) 16 and the multiinstitutional combined induction 
chemoradiation trial from the Lung Cancer Study 
Group (52%) 14 and the CALGB (58%). 24 The long- 
term survival in the patients having complete resection 
agrees with the Memorial Sloan-Kettering Cancer 
Center (MSKCC) single-institution experience after 
complete resection following induction chem0therapy 
(41% 3-year survival). 12 
It is important to note that although the survival 
data of these trials is similar, the Toronto 16 and 
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MSKCC 12 trials involved a variable overall treat- 
ment plan with only two to three cycles of induction 
chemotherapy and no further chemotherapy in pa- 
tients having complete resection. This protocol 
called for adjuvant chemotherapy to all but the 
patients with unresectable l sions, and yet the treat- 
ment toxicities in our trial were less than those 
reported with the mitomycin/vinblastine/cisplatin 
combinations used in the Toronto and MSKCC 
trials. Specifically, less neurotoxicity, ototoxicity, 
and pulmonary toxicity and fewer treatment-related 
deaths occurred in this trial. The incidence of treat- 
ment-related death was 15.4% in the Toronto trial 
and 15% in the CALGB concomitant chemoradia- 
tion trial, compared with a 5.1% incidence in the 
MSKCC trial and a 5.4% incidence in this trial. 
The improved toxicity rates in our trial may be 
due to the lack of mitomycin in the treatment 
regimen. Additionally, there were no cases of post- 
obstructive pneumonitis at study entry. Unlike the 
previous CALGB trial, this trial used sequential 
chemotherapy and radiation therapy instead of con- 
comitant herapy, which may produce less cumuia- 
tive toxicity. 
Roth 19 recently reported a single-institution 
phase III trial of patients with stage IIIA disease. 
The two arms included preoperative chemotherapy 
followed by tesection and adjuvant chemotherapy 
versus surgery alone. Sixty patients (including 16 
patients with T3 N0-1) were accrued before the trial 
was stopped because of compelling differences in 
survival. Survival at 3 years was 56% in the chemo- 
therapy-surgery arm and 15% in the surgery-alone 
group. Although these results further support mul- 
timodality treatment of stage IIIA disease, they also 
point out two caveats for future studies. Only pa- 
tients with surgically documented N2 disease should 
be entered into these protocols, because survivals 
after resection of T3 N0-1 lesions have been shown 
to be different from those with N2 disease. 2'2s The 
utility of a surgery-alone arm in a trial of therapy for 
stage IIIA non-small-cell ung cancer may be sub- 
optimal. 
The Southwest Oncology Group has recently pub- 
lished their most recent phase II trial assessing 
multimodality therapy in stage IIIA and IIIB non- 
small-cell lung cancer. 26 As was the case in this trial, 
all patients had surgical staging of their disease 
before enrollment. Included in the 126 patients 
studied were 51 patients classified with stage IIIB 
disease by either T4 tumor status or N3 nodal 
disease. Their 2-year survivals for IIIB disease with 
T4 (n = 24 patients) or N3 (n = 27 patients) were 
50% and 24%, respectively. 
These most recent phase II trial results add to the 
growing body of evidence that multimodality treat- 
ment regimens in advanced stage non-small-cell 
lung cancer can be performed in a multiinstitutional 
framework with acceptable treatment-related mor- 
bidity and mortality. 
The benefits of multimodality treatment are not 
without cost. This treatment regimen was a long and 
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ditficult course for the patients that participated. 
Only 42% of the entry patients completed the full 
protocol. Eleven patients (15%) discontinued treat- 
ment during neoadjuvant chemotherapy, 12patients 
(16%) discontinued after thoracotomy, six patients 
(8%) discontinued during postoperative chemother- 
apy, and two patients (3%) discontinued before the 
completion of the radiation therapy. The time taken 
for the entire treatment was approximately 200 days 
(6.5 months) with an overall median survival of 15 
months and a chance at a best median survival of 21 
months. However, a substantial subgroup of patients 
seem to have been granted a long-term disease-free 
survival period by the treatment protocol. At the 
time that this trial was designed, there was little 
demand for a reliable measure of the impact of 
treatment on the quality of life of the patient. These 
results highlight he difficulty in assessing the impact 
of new treatments for stage IIIA (N2) disease: the 
balance of the risk of toxicity, early death, and 
negative impact on quality of life to the chance for a 
long period of improved life. A reliable measure to 
quantify the impact of such treatments on the 
quality of life of the patient is sorely needed. 
Combined trimodality therapy trials of surgically 
staged IIIA (N2) non-small-cell lung cancer can be 
conducted efficiently in a multiinstitutional setting. 
Several future directions remain. The survival ben- 
eilt suggested by combined modality phase II trials 
needs to be substantiated bycarefully designed and 
executed multiinstitutional phase III trials. If the 
survival benefit is substantiated, treatment combina- 
tions must then be evaluated for the appropriate 
timing of interventions. Further studies led by cooper- 
ative oncology groups may soon change the standard 
of care for this chaUenging subgroup of patients. 
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Discussion 
Dr. Benedict D. T. Daly (Boston, Mass.) Because stage 
IIIA disease by definition is anatomically resectable, pre- 
sumably the rationale for choosing induction chemother- 
apy as the first treatment modality is to adversely affect 
the metastases likely to be already present in a majority of 
the patients. Judging by the survival results and the 
prevalence of distant metastases on follow-up, it was at 
least efficacious in serving this purpose in 40% of the 
patients. Furthermore, it necessitated a 2-month delay in 
surgical treatment. During this interval, a subset of pa- 
tients (8%) was identified who would not benefit from the 
operation. Thus approximately 50% of the patients ben- 
efited from induction chemotherapy. On the other hand, 
only 73% of the patients undergoing operation had resee- 
tion, and only half of these had eurative resections; The 
induction chemotherapy, therefore, was not efficacious in 
treating the local disease in a majority of the patients. 
Although the disease was downstaged in 22% of the 
patients and 50% of the disease in level 2 and level 7 
nodes was eradicated, 25% of the patients undergoing 
resection had tumor at the margin of resection and one 
third had tumor in the highest hode resected. Postopera- 
tive adjuvant radiation was, however, delayed 2months by 
two cycles of postoperative chemotherapy in those pa- 
tients who had incomplete resection. 
This is an excellent study. It has demonstrated the 
efficacy of chemotherapy in eradicating, or at least delay- 
ing, the emergence ofdistant metastases. But it has shown 
the need for earlier radiation given concomitantly with 
preoperative or postoperative chemotherapy, to provide 
bettet local control and ideally to improve long-term 
results. 
I have three questions. What was found at operation 
that made the lesions in 17 patients unresectable, and do 
you think giving the radiation preoperatively in these 
patients could have improved the resectability rate? Was 
there a difference or trend in survival based on histologic 
characteristics or the number of nodal stations involved 
with tumor? Finally, when you reported that patients had 
diseased margins, were you referring to the bronchial 
mucosa, the stapled fissures, or the peribronchial lymphat- 
ics? 
Dr. Sugarbaker. Thank you very rauch, Dr. Daly. The 
majority of the patients with unresectable disease were 
found to have extension of nodal disease into mediasti- 
num that was not determined by preoperative CT scan- 
ning. It may be that with better imaging, particularly with 
the use of magnetic resonance imaging, we may get a 
better idea of where the nodes are actually involving the 
vena cava; that was the major structure that was involved 
in that group of patients. The proximal carina and trachea 
were also significant structures that were not determined 
to be involved before thoracotomy. 
Dr. Willard A. Fry (Evanston, Ill.). What do you mean 
by T4 nodal involvement? 
Dr. Sugarbaker. The definition is unresectable nodal 
disease that has invaded the mediastinum and is contigu- 
ous with the primary lesion. 
Dr. Fry. Is this local tumor advancement, ot nodal? 
Dr. Sugarbaker. In these patients the nodal disease in 
the mediastinum was involving the cava or the trachea 
and, therefore, was deemed unresectable when the oper- 
ative notes were reviewed. 
The CALGB did not use preoperative radiotherapy to
help downstage these lesions before surgical resection 
because of reports by Wanebo and others that have 
suggested that the perioperative mortality in patients 
receiving concomitant radiation/chemotherapy is substan- 
tial; therefore, a single modality induction treatment 
strategy was used. The efficacy of preoperative radiother- 
apy needs to be evaluated, and in selected patients it may 
be of benefit. Conducting such a trial in a multiinstitu- 
tional setting, where generic onclusions are to be drawn, 
conclusions that will affect a large number of patients 
treated with lung cancer, is problematic given the high 
mortality rates noted. I am not sure it is feasible ven in 
single-institution reports. 
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The trend in survival in terms of nodal stations did not 
hold up in this group of patients. We could not trend 
either the number of mediastinal nodes involved or level 
7 subcarinal nodes, which in some studies have been 
suggested to foretell a very poor prognosis. In terms of the 
number of nodes or nodal stations, there was no correla- 
tion with survival at this time. 
There was no consistent group of diseased margins. 
Some were vascular margins, pulmonary artery margins; 
several were bronchial margins; and there was one stapled 
fissure margin and one margin at the apex. 
Dr. Robert J. Ginsberg (New York, N.Y.). Dr. Sugar- 
baker, I congratulate you for trying to standardize preop- 
erative staging in this difficult group of patients. 
You indicated that in left upper lobe tumors surgeons 
would obtain biopsy tissue from level 5 and then ensure 
that the patient did not have contralateral nodes. How was 
that done? 
Dr. Sugarbaker. It was done by cervical and anterior 
mediastinoscopy. 
Dr. Ginsberg. They obtained biopsy tissue from the 
right four, I would presume, not from levels 2L and 4L. Is 
that correct? 
Dr. Sugarbaker. We encouraged that a biopsy of one 
contralateral node be done. 
Dr. Ginsberg. In left upper lobe tumors, according to 
your paper, complete node dissection was done, including 
levels 5, 4, and 2. Is that correct? 
Dr. Sugarbaker. That is correct. Node sampling was 
attempted in all of those areas. 
Dr. Ginsberg. The manuscript said "dissection," not 
node sampling. 
We have to define what contralateral nodes actually 
means. In the Lung Cancer Study Group map, the midline 
defines the contralateral nodes. I think that within coop- 
erative groups everybody should define what contralateral 
nodes are. I presumed from reading your paper that 
anything in the superior mediastinum was a contralateral 
node, not just right paratracheal, but I may be wrong. 
The other thing to remember is that the prognosis with 
solitary level 5 and 6 node involvement has been well 
defined in many studies now in Europe, Canada, and the 
United States. 
We showed at the recent VATS course that without any 
kind of induction chemotherapy or chemoradiotherapy, 
the overall survival if only levels 5 and 6 are involved is 
better than what you reported for even the best group of 
patients with resected N2 disease and equal that seen for 
resected N1 disease. How many of your patients had only 
level 5 and 6 nodes? 
Dr. Sugarbaker. I think there were only a couple of 
patients. 
Dr. Ginsberg. We must decide whether this group of 
patients hould be involved in induction trials, for unre- 
sectable N2 disease and, if they are, they should be 
stratified because they are such a good prognostic group. 
Dr. Sugarbaker. Are you referring here to single- 
institutional trials or to multiinstitutional trials? 
Dr. Ginsberg. I am just talking about the survival of 
patients with solitary level 5 and 6 nodes as reported by 
Vogt-Moykopf, Patterson, and our own institution, when 
they only have solitary level 5 and 6 nodes. If a trial is 
contaminated by a 1arge number of solitary level 5 and 6 
nodes, there may be a more optimistic result because of it. 
I certainly concur with you that multiinstitutional trials 
should be done. I think it has been well shown now with 
your study and previously with the Lung Cancer Study 
Group and Southwest Oncology Group that induction 
chemotherapy or chemoradiotherapy rotocols can be 
done multiinstitutionally with reasonable mortality. I 
think the large cooperative groups now should concen- 
trate on one phase III trial comparing the combined 
modality approach with what is now standard, or consid- 
ered standard treatment by most places around the world, 
and that is chemoradiotherapy without any operation. I 
think that further phase III trials should be done only if 
new and exciting combinations of chemotherapy or che- 
moradiotherapy appear to be efficacious in nonsurgical 
phase II trials. We have gone through the whole gamut 
now of induction chemotherapy and chemoradiotherapy 
phase II "feasibility" trials, and it is time we answered the 
original question we wanted to answer: Is surgery really 
indicated for "unresectable" N2 disease? 
Dr. Sugarbaker. I would simply react in one way to the 
comment regarding the standard of therapy. Since the 
report of the Barcelona study in the New England Journal 
of Medicine in January 1994, which demonstrated a sur- 
vival advantage to induction chemotherapy followed by 
surgery versus urgery alone, there has been and may be in 
the community a license to proceed with this treatment 
strategy. I am not sure that this is the correct approach, 
but I think it is something that we all need to be aware of. 
Dr. Valerie W. Ruseh (New York, N.Y.). I have a couple 
of comments and one question. With respect o the use of 
concurrent induction chemoradiotherapy, both the South- 
west Oncology Group (J THORA¢ CARDIOVASC SDR6 1993; 
105:97-106) and the Rush-Presbyterian Group (Arm Tho- 
rac Surg 1989;47:669-77) have shown the feasibility and 
effectiveness of this approach. However, other single- 
institution experiences, uch as that reported from the Fox 
Chase Cancer Center (Ann Thorac Surg 1993;55:986-9) 
this past year, suggest hat when chemotherapy is com- 
bined with high-dose radiotherapy (i.e., doses higher than 
45 Gy) the risk of postoperative adult respiratory distress 
syndrome and of bronchial stump leak becomes prohibi- 
tive. Whether chemoradiotherapy is bettet induction 
treatment than chemotherapy alone remains an unan- 
swered question. 
One of the useful points of information from this study 
is that you report the response rates of an induction 
chemotherapy regimen that does not contain mitomycin. 
There has certainly been a lot of controversy about the 
risks and benefits of including mitomycin in the induction 
chemotherapy regimen. This study suggests that the re- 
sectability rate after vinblastine sulfate (Velban) and 
cisplatin is roughly equivalent o that after mitomycin, 
vinblastine, and cisplatin. 
Finally, I have one question: Are you able to determine 
how many patients had bulky N2 disease versus those who 
had single node, intranodal disease only at mediastinos- 
copy? 
Dr. Sugarbaker. We do have information regarding 
whether the patients had bulky disease seen by both plain 
film and CT scan or whether they had microscopic disease. 
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Although there appears to be a survival advantage in the 
patients with microscopic disease, that advantage does not 
hold up statistically. However, there is a trend toward that. 
Your comments regarding multiinstitutional trials, as 
well as those of Dr. Ginsberg, are right on target. Any 
oncologist will tell you that if they take an oncology 
regimen into a multiinstitutional setting, morbidity will 
double and response rates will fall in half. From a surgical 
standpoint, Dr. Rusch and Dr. Ginsberg and others know 
from the Lung Cancer Study Group experience that 
results from single-institution trials of a given treatment 
regimen do not necessarily correlate to results obtained in 
a multiinstitution trial. 
Dr. Donald L. Morton (Santa Monica, Calif.). I notice 
that the disease was downstaged in only about 22% of the 
patients whom you treated preoperatively, and I wonder if 
postoperative therapy would give similar results. What is 
the evidence that chemotherapy lus radiation therapy is 
superior when given before rather than after a complete 
mediastinal node dissection? 
Dr. Sugarbaker. The use of adjuvant radiation and 
chemotherapy has been studied in a number of single- 
institutional trials and was also actually looked at by the 
Lung Cancer Study Group separately, using chemother- 
apy in the adjuvant setting and then radiation, and no 
benefit o survival was noted. There are some theoretical 
advantages to giving neoadjuvant therapy. The intact 
blood supply maximizes drug delivery to the tumor and 
nodal metastases. The actual intervention or the admin- 
istration of chemotherapy comes rauch earlier in the 
natural history of a disease, which has a very short natural 
history, with a life cycle that almost many times spans 18 
to 20 months from diagnosis to death. So by intervening 
earlier with chemotherapy, we may be getting to the 
disease when there is lower tumor bulk. And almost 
regardless of the malignancy tbat has been studied, the 
lower the stage or the lower the tumor bulk, the higher the 
response rate to chemotherapy. In addition, there may be 
some advantage togiving chemotherapy while micrometa- 
static disease in the lymph nodes with the highest mitotic 
index has an intact blood supply, thereby maxirnizing drug 
delivery and effectiveness of therapy. 
Dr. Fry. Eastern Cooperative Oncology Group protocol 
3590, which is available through Intergroup, wherein 
everybody gets radiation and half the subjects get chemo- 
radiation, is maturing. I think that the question that you 
pose will be answered by that multiinstitutional c inical 
trial. 
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